Novavax

+$4.74 (+2.31%) Today
$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Novavax and other stocks, options, and ETFs commission-free!

About NVAX

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome.

CEO
Stanley C. Erck
Employees
791
Headquarters
Gaithersburg, Maryland
Founded
1987

NVAX Key Statistics

Market Cap
15.54B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
3.41M
High Today
$211.27
Low Today
$201.65
Open Price
$205.00
Volume
2.55M
52 Week High
$331.68
52 Week Low
$43.60

NVAX News

ReutersJun 11

UPDATE 1-Novavax says COVID-19 vaccine shows immune response against Beta virus variant

(Adds details on studies) June 11 (Reuters) - Novavax Inc said on Friday its experimental COVID-19 vaccine showed immune response and protection against the hi
MarketWatchJun 11

Novavax Reports Favorable Preclinical and Clinical Data for Vaccine

By Josh Beckerman Novavax Inc. reported favorable preclinical and clinical data for Covid-19 vaccine candidate NVX-CoV2373, including against variants original

NVAX Earnings

-$3.60
-$1.82
-$0.05
$1.73
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Estimated
— per share
Actual
Expected Aug 9, After Hours
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure